Analyst consensus rating
Braveheart Bio Analyst Rating: none
Direct answer
Braveheart Bio's consensus rating is none.
4 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $45.25.
Forecast evidence checked September 28, 2026.
Get free Braveheart Bio email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $21.07
- Average price target
- $45.25
- High price target
- $48.00
- Low price target
- $40.00
- Low target gap
- +89.8%
- Target upside
- +114.8%
- High target gap
- +127.8%
- Target range width
- 38%
- Consensus rating
- none
- Analysts
- 4
- Evidence date
- September 28, 2026
- Valid through
- October 5, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Braveheart Bio?
Braveheart Bio has a verified none consensus. The same dataset has an average price target of $45.25.
How far are Braveheart Bio's low and high targets from the recorded price?
The low target implies +89.8%, while the high target implies +127.8%.
How many analysts are included in Braveheart Bio's consensus?
The verified consensus includes 4 analysts.
How is Braveheart Bio's target upside or downside calculated?
The average target of $45.25 is divided by the recorded price of $21.07, then one is subtracted to produce +114.8%. This does not guarantee a future return.
When was Braveheart Bio's analyst forecast verified?
The data was verified on 2026-09-28. The dataset is valid through 2026-10-05.